Loading…
Diversified pharma company running CDMO manufacturing, specialty generics and radiopharmaceuticals under the Jubilant Bhartia Group.
Diversified pharma company running CDMO manufacturing, specialty generics and radiopharmaceuticals under the Jubilant Bhartia Group.
Spread across services and products: its US contract manufacturing, with sterile injectables and allergy products from a Spokane, Washington plant, works for other drug companies, while its radiopharmacy business supplies hospitals with diagnostic isotopes. The group has been working to reduce debt.
In one line: A diversified Indian CDMO/radiopharma conglomerate arm.
Moat: narrow (regulatory licence, process know-how). Radiopharma manufacturing/distribution licences and CDMO plants are difficult and slow to replicate.
Headquarters: Noida, India · Founded: 2020 · Employees: 6,386
Size Jubilant Pharmova (JUBLPHARMA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.58B, the 444th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹939.60 on 6 Nov 2026.
Performance Over six months the shares fell 4.2%, against -4.8% for the median peer and 0.0% for the India market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 16.3% over the last twelve months (peer median +1.8%); the operating margin is 8.7% (peer median 11.0%).
Valuation It trades at 29.0× forward earnings against a peer median of 23.2× (5th most expensive of 13).
Capital Return on invested capital runs 5.7 points below its cost of capital (13.6% WACC).
Next results Next results expected around 13 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹86.1B | ₹82.7B | ₹72.3B | ₹67.0B | ₹62.6B |
| Revenue growth | — | +14% | +8% | +7% | — |
| Gross profit | ₹25.0B | ₹17.3B | ₹16.5B | ₹13.6B | ₹9.81B |
| EBITDA | ₹12.2B | ₹12.1B | ₹10.4B | ₹8.96B | ₹7.61B |
| Net income | ₹3.52B | ₹3.98B | ₹8.39B | ₹771M | -₹610M |
| Free cash flow | n/a | -₹4.36B | -₹2.41B | -₹1.44B | -₹3.78B |
| Capital expenditure | n/a | ₹14.5B | ₹11.2B | ₹8.98B | ₹8.14B |
| Total debt | n/a | ₹36.1B | ₹27.3B | ₹36.6B | ₹36.8B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Jubilant Pharmova JUBLPHARMA.NS | $1.58B | -4% | +16% | 9% | 29.0× | n/a |
| Piramal Pharma PPLPHARMA.NS | $3.37B | +30% | +9% | 3% | 159.9× | n/a |
| Syngene International SYNGENE.NS | $1.78B | -11% | -6% | 13% | 67.8× | 35.3% |
| Lantheus LNTH | $6.57B | +8% | +2% | 19% | 17.5× | -0.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | JUBLPHARMA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.6% | +4.8% | 4th lowest of 21 |
| 6-month return | -4.2% | -4.8% | 10th highest of 20 |
| Distance from 52-week high | -20.6% | -22.1% | 11th highest of 21 |
| Revenue growth (TTM) | +16.3% | +1.8% | 6th highest of 20 |
| Operating margin | 8.7% | 11.0% | 8th lowest of 20 |
| Forward P/E | 29.0× | 23.2× | 5th most expensive of 13 |
| ROIC minus cost of capital | -5.7 pp | +1.4 pp | 8th lowest of 20 |
| EV / EBITDA | 12.3× | 32.3× | 2nd cheapest of 7 |
| Net debt / EBITDA | 1.9× | -1.5× | most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.58B | -4% | +16% | 9% | 29.0× | n/a | n/a |
| LigaChem Biosciences 141080.KS | South Korea | $1.59B | -68% | -33% | -208% | n/a | n/a | n/a |
| Xiamen Kingdomway 002626.SZ | China | $1.58B | +15% | -3% | 11% | 30.0× | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.58B | +40% | +17% | 18% | 63.7× | 37.6% | +16.6% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.60B | -5% | +16% | 24% | n/a | -4.1% | +0.2% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.56B | -5% | +4% | 9% | 18.5× | -5.8% | +1.9% |
| Indegene INDGN.NS | India | $1.56B | +15% | +36% | 12% | 27.5× | 29.6% | +29.4% |
| Eton Pharmaceuticals ETON | United States | $1.61B | +236% | +81% | 16% | 27.9× | 39.6% | +359.6% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.62B | -4% | +7% | 17% | 16.2× | -4.5% | +6.8% |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.55B | +53% | -6% | -19% | n/a | 49.9% | -13.2% |
| Nanobiotix NANO.PA | France | $1.54B | -42% | -77% | -392% | n/a | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.53B | -17% | +2% | -2% | 42.9× | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.52B | +22% | +16% | -64% | n/a | n/a | n/a |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +5% | +15% | 35% | 9.2× | -15.1% | +13.5% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.67B | -14% | -13% | 6% | 13.2× | -6.0% | -5.6% |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.67B | +1% | -4% | 15% | 47.5× | 6.7% | -4.3% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| NATCO Pharma NATCOPHARM.NS | India | $1.68B | -30% | -21% | 25% | 18.8× | 15.3% | +19.0% |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.49B | -17% | +1% | 19% | 13.0× | -8.5% | +4.6% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.69B | -25% | +31% | 10% | n/a | 49.3% | +23.0% |
| ABL Bio 298380.KS | South Korea | $1.49B | -73% | -64% | -251% | n/a | n/a | n/a |